Real-time ultrasound-guided stellate ganglion block for migraine: an observational study

Jiawei Hou¹, Shaofeng Pu², Xingguo Xu³, Zhiqiang Lu⁴† and Junzhen Wu²*†

Abstract
Objective: To observe whether ultrasound-guided stellate ganglion block (SGB) can effectively relieve migraine pain and improve the quality of migraine patients' life.

Methods: 81 patients with migraines were enrolled in this study. The patients received SGB with 6 ml of 0.15% ropivacaine once every week for four times. Migraine was assessed with the Migraine Disability Assessment Scale (MIDAS) at baseline and three-months follow-up (Tm). The numerical rating scale (NRS) score at baseline, one day after treatment (Td) and Tm, the frequency of analgesic use in 3 months and the side effects were also recorded at the same time.

Results: The NRS score of migraine subjects decreased significantly from 7.0 (2.0) to 3.0 (1.0) at Td and 2.0 (2.0) at Tm (vs baseline, \( P < 0.01 \)). The MIDAS total scores were 14.0 (10.5) at baseline and 7.0 (4.5) at Tm (\( P < 0.001 \)). During the three months, the frequency of analgesic consumption was decreased from 6.2 ± 2.8 to 1.9 ± 1.8. There were no serious side effects.

Conclusions: This study confirmed that ultrasound-guided SGB is an effective method to treat migraines. This technique can reduce pain and disability and then improve the quality of life of patients with migraines.

Keywords: Ultrasound guidance, Stellate ganglion block (SGB), Migraine

Introduction
Migraine is a nervous system disease characterized by headache, nausea, vomiting and sensitivity to visual, auditory, olfactory and skin irritation. It is usually recurrent with moderate to severe pain and poor drug control. Migraine is the third leading cause of disability globally. It affects hundreds of millions of people and accounts for about 10% of the world's population [1, 2]. In addition, migraine-related disability and malpractice cause substantial financial costs [3]. Although there are some drugs for acute treatment and prevention of migraine, other treatment options for patients with poor drug response or intolerance to drug treatment should be considered [4].

Stellate ganglion block (SGB) is a safe procedure that may provide extended relief for breast cancer-related lymphedema (BCRL) and all clusters of Post-Traumatic Stress Disorder (PTSD) symptoms [5, 6]. SGB is also an accepted intervention for the treatment of various pain conditions of the head and neck regions as well as the upper limbs [7]. The stellate ganglion is a sympathetic ganglion, approximately 2.5 cm in length, 1 cm in width and 0.5 cm in thickness. It is located in front of the neck of the first rib and can extend to the seventh cervical spine (C7) [8]. Yu et al. reported that ultrasound-guided SGB could effectively relieve cervical headache.
[9]. However, the time point of pain assessment was 1 day after SGB, with no long-term follow-up data. A successful case of stellate ganglion block for difficult therapy of refractory tension headache was reported in 2019 [10]. One study showed that bilateral SGB was effective to reduce pain and improve the Migraine Disability Assessment Scale (MIDAS) score in two migraine patients [4]. However, evidence regarding the effect of SGB on migraines is scanty. Herein, we investigate whether SGB can reduce acute migraine attacks and whether it can effectively reduce the frequency of migraine attacks within three months.

Methods
Patients were enrolled between June 15, 2017 and March 20, 2019. The inclusion criteria were participants over 18 years old, diagnosed with migraine. Diagnoses of migraine were made by expert physicians according to the ICHD criteria [11].

The exclusion criteria included patients with a space-occupying lesion, coagulation disorders, systemic or local infection and drug allergies. Psychotic patients and migraine with bilateral attacks were also excluded from this study.

All patients were administered with SGB on the affected side and 0.15% ropivacaine was injected. SGB was conducted once a week for 4 times. All patients were followed up for 3 months. Analgesics such as diclofenac sodium were taken orally if the migraine attacks and the pain was serious, but no more than 10 times per month to avoid medication overuse headache.

Data recording
The primary outcome was the MIDAS score at 3-months follow-up (Tm). The MIDAS questionnaire is one of the most widely used to measure the decline of quality of life caused by migraine [12]. The MIDAS questionnaire is a short, self-administered questionnaire designed to quantify headache-related disability within 3 months. It includes five questions about work, household and non-work activity (social, family and leisure activities) to assess the degree of disability caused by headaches. The MIDAS score is closely related to the judgment of the severity of the headache and the need for medical care [13] and has been widely used in China [14–16].

Secondary outcomes include the numerical rating scale (NRS) score at baseline, one day after treatment (Td) and 3 months after treatment (Tm). The NRS allows the subject to rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain) [17]. We defined migraine with an NRS score >7 as severe migraine. The frequency of non-steroidal anti-inflammatory drugs (NSAIDs) consumption in 3 months was also recorded. During the follow-up period, SGB-related side effects such as hoarseness, dysphagia and foreign body sensation in the throat, upper limb weakness and hematoma formation were confirmed and recorded by doctors. Serious complications such as general spinal anesthesia, epidural block and pneumothorax were reported to the ethics committee. Patients were asked to inform doctors of any adverse symptoms they had experienced at any time.

Procedures
Ultrasound-guided SGB
The patient’s position was similar to that of the traditional blind method. Patients were positioned in a lateral position with their necks slightly hyperextended. Assisted by ultrasound imaging equipment and a 7–14 MHz linear array probe (5 Nerve, SonoSite, USA), the C7 level was confirmed. Because of the tiny or absent anterior tubercle of the C7, sonoanatomy of the C7 transverse process was similar to the traditional Chinese “imperial concubine chair”. The thyroid gland, carotid artery, compressible internal jugular vein, vertebral artery, brachial plexus and the oval-shaped structure of the longus colli muscle were revealed on this short-axis view. The color Doppler mode was used before needling to avoid penetrating blood vessels such as the vertebral artery, internal jugular vein and inferior thyroid vessel (Fig. 1).

Ultrasound can provide the perfect technical means to achieve this goal. We used a 25-gauge, 8-cm needle for a puncture, and the puncture point was 1–1.5 cm away from the ultrasound probe. The in-plane puncture technique was used for real-time display of the whole process of puncture. The tip of the needle reached the surface of the longus colli muscle and the 5 o'clock position of the carotid artery (Fig. 2a). Under the guidance of the ultrasound, SGB was performed by injection of 6 ml of 1.5% ropivacaine. The common carotid artery was observed “floating” upward under ultrasound, indicating that the drug diffused in the prevertebral space on the surface of the longus colli muscle (Fig. 2b). All measurements were performed by a senior anesthesiologist using the same ultrasound instrument.

Statistical analysis
MIDAS and NRS scores are expressed as median with interquartile range (IQR). A generalized linear mixed model (GLMM) was performed to evaluate changes in pain NRS scores over repeated measurements. If the repeated measures demonstrated a statistically significant time interaction, multiple comparison corrections were performed using Bonferroni correction. Changes in migraine outcomes as assessed by the MIDAS questionnaire were compared using a paired Wilcoxon test.
or signed rank-sum test. A \( P \)-value < 0.05 was considered statistically significant. Statistical analyses were conducted using SPSS 18.0 software for Windows (SPSS Inc., Chicago, IL, USA).

Results

Subject characteristics

We recruit 186 subjects. After preliminary investigation, 107 subjects were assessed for eligibility. However, among 107 subjects, 15 subjects did not meet the inclusion criteria and the informed consent form was not obtained from 5 subjects. Therefore, 86 subjects were finally enrolled in the study. Of 86 patients, 6 patients did not complete all the four SGB and 2 patients lost follow-up, and therefore 81 patients (23 men, 58 women; median age, 33.2 ± 7.9 years; range, 18–62 years) were included in the final analysis (Fig. 3).

Within three months, 17 patients had severe migraine attacks < 3 times, 44 patients had severe migraine attacks 3–6 times, 11 patients had severe migraine attacks 7–12 times and 9 patients had severe migraine attacks > 12 times (Table 1).

Clinical assessment

MIDAS total scores of subjects were 14.0 (10.5) at baseline and 7.0 (4.5) at Tm \((P<0.001)\) (Table 2). NRS scores
at baseline, Td and Tm were 7.0 (2.0), 3.0 (1.0) (vs baseline, \( P < 0.01 \)) and 2.0 (2.0) (vs baseline, \( P < 0.01 \)), respectively (Table 3). The frequency of analgesic use within 3 months was 6.2 \( \pm \) 2.8 at baseline and 1.9 \( \pm \) 1.8 at Tm.

Of the 86 patients recruited, two patients developed headaches after receiving a single SGB treatment and gave up follow-up treatment. Among the 81 patients who were included in the final analysis, there were 6 cases of hoarseness, 3 cases of local bruise and 2 cases of transient upper limb numbness. There were no serious complications such as gastrorrhagia, general spinal anesthesia, epidural block and pneumothorax.

**Table 1** Demographic characteristics

|                     | Frequency (n) | Proportion (%) |
|---------------------|---------------|----------------|
| Gender              |               |                |
| Male                | 58            | 71.6           |
| Female              | 23            | 28.4           |
| Age                 |               |                |
| 18–28               | 19            | 23.5           |
| 29–38               | 46            | 56.8           |
| 39–48               | 12            | 14.8           |
| >48                 | 4             | 4.9            |
| Frequency of severe headache per quarter (NRS>7) | | |
| <3                  | 17            | 21.0           |
| 3–6                 | 44            | 54.3           |
| 7–12                | 11            | 13.6           |
| >12                 | 9             | 11.1           |

**Table 2** Migraine outcomes as assessed by the MIDAS questionnaire

| MIDAS scores                                                                 | SGB (n = 81) | Z-Value | p-Value |
|--------------------------------------------------------------------------------|--------------|---------|---------|
| Total score                                                                   | 14.0 (10.5)  | 7.0 (4.5)| 7.553 < 0.001 |
| On how many days in the last 3 months did you miss work or school because of your headaches? | 1.0 (1.0) | 0.0 (0.0) | 5.781 < 0.001 |
| How many days in the last 3 months was your productivity at work or school reduced by half or more because of your headaches? | 3.0 (2.0) | 3.0 (2.0) | 5.955 < 0.001 |
| On how many days in the last 3 months did you not do household work because of your headaches? | 3.0 (3.0) | 1.0 (2.0) | 7.026 < 0.001 |
| How many days in the last 3 months was your productivity in household work reduced by half or more because of your headaches? | 6.0 (5.0) | 2.0 (2.0) | 7.656 < 0.001 |
| On how many days in the last 3 months did you miss family, social, or leisure activities because of your headaches? | 2.0 (2.0) | 1.0 (2.0) | 5.276 < 0.001 |

MIDAS Scores are expressed as median (IQR)

Tb Baseline, Tm Three-months follow-up, MIDAS Migraine Disability Assessment Scale, SGB stellate ganglion block
The stellate ganglion is extensively connected with the cerebral cortex, hypothalamus, amygdala and hippocampus [28]. SGB can effectively treat postherpetic neuralgia, hot flushes and night awakenings in survivors of breast cancer, tension headache and PTSD, in part by improving blood supply and inhibiting the connection between the stellate ganglion and the brain through sympathetic action within its innervation; however, the exact mechanism remains unclear [5, 6, 10, 29–31]. Low melatonin levels have been reported in migraine patients and SGB has been shown to restore melatonin rhythm. Melatonin can effectively prevent migraines by inhibiting the synthesis of nitric oxide and the release of calcitonin-related peptides and antagonizing excitotoxicity caused by glutamate [32–34]. In addition, stress is the most common migraine trigger. In response to stress, sympathetic activity increases, leading to the release of migraine-associated neurotransmitters, such as dopamine and prostaglandins [35–37]. High dopamine levels can lead to nausea and vomiting, while increased prostaglandins can increase pain sensitivity and inflammation in migraine patients. SGB can regulate sympathetic nerve activity, thereby alleviating most of the symptoms in migraine patients. In this study, we did not detect melatonin, prostaglandins and dopamine levels as in previous studies. We look forward to further research in this field in the future.

MIDAS was designed to quantify headache-related disability over 3 months. The reliability and internal consistency of the MIDAS score are comparable to those of a previous questionnaire (Headache Impact Questionnaire). However, the MIDAS score requires fewer questions, is easier to score and provides intuitively meaningful information on lost days of activity in three domains [38, 39]. The MIDAS questionnaire was considered highly reliable and effective and was relevant to clinical judgment on medical care needs. In our study, the MIDAS score of patients was significantly decreased at 3-months follow-up. Besides, NRS scores decreased significantly one day and 3 months after SGB. The frequency of analgesic use was also significantly decreased after 3 months. These results suggest that SGB once a week for 4 weeks can reduce the headache and disability among migraine patients and improve their work and quality of life.

Two patients who were recruited but not included in the analysis experienced migraine aggravation after a...
single SGB treatment, suggesting that migraine has more complex mechanisms. Wulf et al. detailed complications after SGB. Most of them were related to the central nervous system (such as convulsions). Other serious complications included high-level subarachnoid block, high-level epidural block, pneumothorax and allergic reaction. All SGBs were performed without fluoroscopy [40]. In our study, serious complications such as subarachnoid block, epidural block and convulsion were not observed. It is suggested that ultrasound-guided SGB is safer than fluoroscopy because ultrasound can clearly distinguish nerves, blood vessels and muscles, and monitor the puncture needle in real-time, while fluoroscopy has no such functions.

Conclusions
In summary, the findings of this study suggest that real-time ultrasound-guided SGB may be an effective treatment option for migraine patients without serious complications. However, further studies should be performed to verify this hypothesis.

Limitations
This study was not a randomized controlled study, and only a few cases were included.

Acknowledgments
We gratefully acknowledge Xuan Chen for her comments on the manuscript.

Authors' contributions
Jiawei Hou wrote the main manuscript text. Xingguo Xu was responsible for data statistics. Shaofeng Pu and Zhiqiang Lu were responsible for patient recruitment. Junzheng Wu and Zhiqiang Lu were responsible for puncture operation and Figs. 1, 2 and 3. Junzheng Wu was responsible for article check. All authors reviewed and approved the manuscript.

Funding
This work was supported through a grant from Shanghai Municipal Health Commission, No. 201840248.

Availability of data and materials
We are willing to share individual deidentified participant data, such as the age of the subjects and MAIDS score and NRS score. We will share the data within three months after the accept of the article and keep it for at least three years. The data can be accessible at www.medresman.org.cn/pub/cn/proj/searchSH.aspx.

Declarations
Ethics approval and consent to participate
This study was approved by the ethics committee of Shanghai Sixth People's Hospital (No. 2016–44) and registered in the Chinese Clinical Trial Registry (Identifier: ChiCTR-IOR-17101536). All subjects were from Shanghai Sixth People's Hospital and Shanghai Eighth People's Hospital. All procedures involving human studies were following the ethical standards of the national research committee. Written informed consent was obtained from all subjects according to the Helsinki declaration. All medical records were anonymous and no subject information was extracted except for the study purpose.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflicts of interest.

Author details
1 Department of Anesthesiology, The Third People's Hospital of Tongzhou District, Nantong City 226311, Jiangsu Province, China. 2 Department of Pain Management, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China. 3 Department of Anesthesiology, Affiliated Hospital of Nantong University, Nantong 226001, China. 4 Department of Anesthesiology, Shanghai Eighth People's Hospital, Shanghai 200233, China.

Received: 29 November 2021 Accepted: 21 March 2022
Published online: 24 March 2022

References
1. Collaborators GBDMM. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1775–812.
2. Silberstein SD. Migraine. Lancet. 2004;363:381–91.
3. Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neuront Clin. 2019;37:631–49.
4. Moon S, Lee J, Jeon Y. Bilateral stellate ganglion block for migraine: a case report. Medicine. 2020;99:e20023.
5. Lynch JH, Mulvaney SW, Kim EH, et al. Effect of stellate ganglion block on specific symptom clusters for treatment of post-traumatic stress disorder. Mil Med. 2016;181:1135–41.
6. Park MW, Lee SU, Kwon S, et al. Comparison between the effectiveness of complex decongestive therapy and stellate ganglion block in patients with breast Cancer-related lymphedema: a randomized controlled study. Pain Physcian. 2019;22:255–63.
7. Aeschbach A, Mekhall NA. Common nerve blocks in chronic pain managemeny. Anesthesiology clinics of north. America. 2000;18:429–59 viii.
8. Slappendel R, Thijsse HC, Crul BJ, et al. The stellate ganglion in magnetic resonance imaging: a quantification of the anatomic variability. Anesthesiology. 1995;83:424–6.
9. Yu Q, Zheng E, Li X, et al. Ultrasound image guided lateral cervical approach to stellate ganglion block for cervical headache. Neurosci Lett. 2020;735:135139.
10. Ueshima H. A successful case of stellate ganglion block for difficult therapy of refractory tension headache. J Clin Anesth. 2019;54:149.
11. Headache classification committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211. https://doi.org/10.1177/0333102417738202, http://www.ncbi.nlm.nih.gov/pubmed/29368949.
12. Stewart WF, Lipton RB, Kolodner KB, et al. Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41–52.
13. Lipton RB, Stewart WF, Sawyer J, et al. Clinical utility of an instrument assessing migraine disability: the migraine disability assessment (MIDAS) questionnaire. Headache. 2001;41:854–61.
14. Yang Y, Song M, Fan Y, et al. Occipital nerve stimulation for migraine: a systematic review. Pain Pract. 2016;16:509–17.
15. Li W, Diao X, Chen C, et al. Changes in hormones of the hypothalamic-pituitary-gonadal axis in migraine patients. J Clin Neurosci. 2018;50:165–71.
16. Zhao E, Xie H, Zhang Y. A Nomogram for the prediction of cessation of migraine among patients with patent foramen Ovale after percutaneous closure. Front Neurol. 2020;11:593074.
17. Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short Form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res. 2011;63(Suppl 11):S240–52.
18. Singer AB, Buse DC, Seng EK. Behavioral treatments for migraine management: useful at each step of migraine care. Curr Neurol Neurosci Rep. 2015;15:14.
19. Dach F, Eckeli AL, Ferreira Kdos S, et al. Nerve block for the treatment of headaches and cranial neuralgias - a practical approach. Headache. 2015;53(Suppl 1):9–71.

20. Allen SM, Mookadam F, Cha SS, et al. Greater occipital nerve block for acute treatment of migraine headache: a large retrospective cohort study. J Am Board Fam Med. 2018;31:211–8.

21. Li J, Yin Y, Ye L, et al. Pulsed radiofrequency of C2 dorsal root ganglion under ultrasound guidance for chronic migraine: a case report. J Pain Res. 2018;11:1915–9.

22. Raposio E, Bertozzi N. Trigger site inactivation for the surgical therapy of occipital migraine and tension-type headache: our experience and review of the literature. Plast Reconstr Surg Glob Open. 2019;7:e2507.

23. Lehmann LJ, Warfield CA, Bajwa ZH. Migraine headache following stellate ganglion block for reflex sympathetic dystrophy. Headache. 1996;36:335–7.

24. Pu S, Wu J, Han Q, et al. Ultrasonography-guided radiofrequency ablation for painful stump neumorai to relieve Postsacral postamputation pain. a pilot study. J Pain Res. 2020;13:3457–45.

25. Pu S, Wu Y, Han Q, et al. Ultrasound-guided Extraforaminal thoracic nerve root block through the midpoint of the inferior articular process and the parietal pleura: a clinical application of thoracic paravertebral nerve block. J Pain Res. 2022;15:533–44.

26. Lee HK, Kim KY, Song JH, et al. Minimal volume of local anesthetic required for an ultrasound-guided SGB. Pain Med. 2012;13:381–8.

27. Yoo J, Lee CS, Kim YC, et al. A randomized comparison between 4, 6 and 8 mL of local anesthetic for ultrasound-guided stellate ganglion block. J Clin Med. 2019;8(9):1314. https://doi.org/10.3390/jcm8091314.

28. Westerhaus MJ, Loevey AD. Central representation of the sympathetic nervous system in the cerebral cortex. Brain Res. 2001;903:117–27.

29. Makharita MY, Amr YM, El-Bayoumy Y. Effect of early stellate ganglion blockade for face pain with acute herpes zoster and incidence of postherpetic neuralgia. Pain Physician. 2012;15:467–74.

30. Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol. 2008;9:523–32.

31. Lipov EG, Navaie M, Brown PR, et al. Stellate-ganglion block improves refractory post-traumatic stress disorder and associated memory dysfunction: a case report and systematic literature review. Mil Med. 2013;178:e260–4.

32. Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: a systematic review. Medicine. 2019;4:e14099.

33. Uchida K, Tateda T, Hino H. Novel mechanism of action hypothesized for stellate ganglion block related to melatonin. Med Hypotheses. 2002;59:446–9.

34. Miano S, Parisi P, Pelliccia A, et al. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci. 2008;29:285–7.

35. Sherbourne CD, Gonzales R, Goldyne ME, et al. Norepinephrine-induced increase in sympathetic neuron-derived prostaglandins is independent of neuronal release mechanisms. Neurosci Lett. 1992;139:188–90.

36. Sheridan DC, Laurie A, Pacheco S, et al. Relative effectiveness of dopamine antagonists for pediatric migraine in the emergency department. Pediatr Emerg Care. 2018;34:165–8.

37. Antonova M, Wienecke T, Olesen J, et al. Prostaglandins in migraine: update. Curr Opin Neurol. 2013;26:269–75.

38. Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the migraine disability assessment (MIDAS) score. Neurology. 1999;53:988–94.

39. Ford JH, Jackson J, Milligan G, et al. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57:1532–44.

40. Wulf H, Maier C. Complications and side effects of stellate ganglion blockade: Results of a questionnaire survey. Anaesth. 1992;41:146–51.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.